Cited 0 times in
Stereotactic radiosurgical treatment of parenchymal brain metastases from prostate adenocarcinoma.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, SH | - |
dc.contributor.author | Chao, ST | - |
dc.contributor.author | Toms, SA | - |
dc.contributor.author | Vogelbaum, MA | - |
dc.contributor.author | Barnett, GH | - |
dc.contributor.author | Suh, JH | - |
dc.contributor.author | Weil, RJ | - |
dc.date.accessioned | 2010-12-29T04:18:00Z | - |
dc.date.available | 2010-12-29T04:18:00Z | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 0090-3019 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/889 | - |
dc.description.abstract | BACKGROUND: Prostate cancer metastatic to the brain is uncommon and has been associated historically with a poor prognosis. It has been suggested that SRS may be an effective treatment.
METHODS: We analyzed a prospective, institutional review board-approved database of patients treated with SRS and identified 5 patients with prostate cancer metastasis. Clinical, pathologic, radiographic, treatment, and outcome information regarding the primary/systemic disease status, and brain metastases were collected. RESULTS: Mean age at the time of treatment for CNS parenchymal metastasis was 72.0 +/- 8.3 years and lesions developed 82.0 +/- 65.1 months after the initial tumor was identified. Four patients had a single lesion and 1 had 4; 3 patients were treated with SRS alone, 1 with WBRT and SRS, and 1 with surgery, then WBRT and SRS. All were symptomatic. Stereotactic radiosurgery controlled the brain metastases in all 5 patients, with functional improvement and with a typical increase of 1 grade in the Karnofsky performance score. Mean survival was at least 10.0 +/- 6.7 months (range, 6-22+ months). Two patients died of conditions unrelated to prostate cancer and 2 of systemic disease progression; 1is alive and asymptomatic. There were no local SRS failures and no new CNS lesions. CONCLUSIONS: Stereotactic radiosurgery for prostate cancer metastatic to the brain, alone or in combination with brain radiation therapy and surgery, is a safe, effective treatment that improves neurologic symptoms and function and may prolong survival. | - |
dc.language.iso | en | - |
dc.subject.MESH | Adenocarcinoma | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Brain Neoplasms | - |
dc.subject.MESH | Cohort Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prostatic Neoplasms | - |
dc.subject.MESH | Radiosurgery | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Stereotactic radiosurgical treatment of parenchymal brain metastases from prostate adenocarcinoma. | - |
dc.type | Article | - |
dc.identifier.pmid | 18262258 | - |
dc.identifier.url | http://linkinghub.elsevier.com/retrieve/pii/S0090-3019(07)00544-7 | - |
dc.contributor.affiliatedAuthor | 김, 세혁 | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1016/j.surneu.2007.05.035 | - |
dc.citation.title | Surgical neurology | - |
dc.citation.volume | 69 | - |
dc.citation.number | 6 | - |
dc.citation.date | 2008 | - |
dc.citation.startPage | 641 | - |
dc.citation.endPage | 646 | - |
dc.identifier.bibliographicCitation | Surgical neurology, 69(6). : 641-646, 2008 | - |
dc.identifier.eissn | 1879-3339 | - |
dc.relation.journalid | J000903019 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.